O	0	12	Angiogenesis	Angiogenesis	NN	B-NP
O	13	23	inhibitors	inhibitor	NNS	I-NP
O	23	24	:	:	:	O
O	25	32	current	current	JJ	B-NP
O	33	43	strategies	strategy	NNS	I-NP
O	44	47	and	and	CC	O
O	48	54	future	future	JJ	B-NP
O	55	64	prospects	prospect	NNS	I-NP
O	64	65	.	.	.	O

O	67	79	Angiogenesis	Angiogenesis	NN	B-NP
O	80	83	has	have	VBZ	B-VP
O	84	90	become	become	VBN	I-VP
O	91	93	an	an	DT	B-NP
O	94	104	attractive	attractive	JJ	I-NP
O	105	111	target	target	NN	I-NP
O	112	115	for	for	IN	B-PP
O	116	120	drug	drug	NN	B-NP
O	121	128	therapy	therapy	NN	I-NP
O	129	136	because	because	IN	B-PP
O	137	139	of	of	IN	I-PP
O	140	143	its	its	PRP$	B-NP
O	144	147	key	key	JJ	I-NP
O	148	152	role	role	NN	I-NP
O	153	155	in	in	IN	B-PP
B-Cancer	156	161	tumor	tumor	NN	B-NP
O	162	168	growth	growth	NN	I-NP
O	168	169	.	.	.	O

O	170	172	An	An	DT	B-NP
O	173	182	extensive	extensive	JJ	I-NP
O	183	188	array	array	NN	I-NP
O	189	191	of	of	IN	B-PP
O	192	201	compounds	compound	NNS	B-NP
O	202	204	is	be	VBZ	B-VP
O	205	214	currently	currently	RB	B-ADVP
O	215	217	in	in	IN	B-PP
O	218	229	preclinical	preclinical	JJ	B-NP
O	230	241	development	development	NN	I-NP
O	241	242	,	,	,	O
O	243	247	with	with	IN	B-PP
O	248	252	many	many	JJ	B-NP
O	253	256	now	now	RB	B-ADVP
O	257	265	entering	enter	VBG	B-VP
O	266	269	the	the	DT	B-NP
O	270	276	clinic	clinic	NN	I-NP
O	277	280	and	and	CC	O
O	280	281	/	/	SYM	B-NP
O	281	283	or	or	CC	O
O	284	293	achieving	achieve	VBG	B-VP
O	294	302	approval	approval	NN	B-NP
O	303	307	from	from	IN	B-PP
O	308	311	the	the	DT	B-NP
O	312	314	US	US	NNP	I-NP
O	315	319	Food	Food	NNP	I-NP
O	320	323	and	and	CC	I-NP
O	324	328	Drug	Drug	NNP	I-NP
O	329	343	Administration	Administration	NNP	I-NP
O	343	344	.	.	.	O

O	345	352	Several	Several	JJ	B-NP
O	353	363	regulatory	regulatory	JJ	I-NP
O	364	367	and	and	CC	I-NP
O	368	377	signaling	signal	VBG	I-NP
O	378	387	molecules	molecule	NNS	I-NP
O	388	397	governing	govern	VBG	B-VP
O	398	410	angiogenesis	angiogenesis	NN	B-NP
O	411	414	are	be	VBP	B-VP
O	415	417	of	of	IN	B-PP
O	418	426	interest	interest	NN	B-NP
O	426	427	,	,	,	O
O	428	437	including	include	VBG	B-PP
O	438	444	growth	growth	NN	B-NP
O	445	452	factors	factor	NNS	I-NP
O	453	454	(	(	(	O
O	454	456	eg	eg	FW	B-NP
O	456	457	,	,	,	O
O	458	466	vascular	vascular	JJ	B-NP
O	467	478	endothelial	endothelial	JJ	I-NP
O	479	485	growth	growth	NN	I-NP
O	486	492	factor	factor	NN	I-NP
O	492	493	,	,	,	O
O	494	502	platelet	platelet	NN	B-NP
O	502	503	-	-	HYPH	B-VP
O	503	510	derived	derive	VBN	B-NP
O	511	517	growth	growth	NN	I-NP
O	518	524	factor	factor	NN	I-NP
O	524	525	,	,	,	O
O	526	536	fibroblast	fibroblast	NN	B-NP
O	537	543	growth	growth	NN	I-NP
O	544	550	factor	factor	NN	I-NP
O	550	551	,	,	,	O
O	552	555	and	and	CC	O
O	556	565	epidermal	epidermal	JJ	B-NP
O	566	572	growth	growth	NN	I-NP
O	573	579	factor	factor	NN	I-NP
O	579	580	)	)	)	O
O	580	581	,	,	,	O
O	582	590	receptor	receptor	NN	B-NP
O	591	599	tyrosine	tyrosine	NN	I-NP
O	600	607	kinases	kinase	NNS	I-NP
O	607	608	,	,	,	O
O	609	612	and	and	CC	O
O	613	626	transcription	transcription	NN	B-NP
O	627	634	factors	factor	NNS	I-NP
O	635	639	such	such	JJ	B-PP
O	640	642	as	as	IN	I-PP
O	643	650	hypoxia	hypoxia	NN	B-NP
O	651	660	inducible	inducible	JJ	I-NP
O	661	667	factor	factor	NN	I-NP
O	667	668	,	,	,	O
O	669	671	as	as	RB	B-CONJP
O	672	676	well	well	RB	I-CONJP
O	677	679	as	as	IN	I-CONJP
O	680	689	molecules	molecule	NNS	B-NP
O	690	698	involved	involve	VBN	B-VP
O	699	701	in	in	IN	B-PP
O	702	709	mitogen	mitogen	NN	B-NP
O	709	710	-	-	HYPH	B-NP
O	710	719	activated	activate	VBN	I-NP
O	720	727	protein	protein	NN	I-NP
O	728	734	kinase	kinase	NN	I-NP
O	735	736	(	(	(	O
O	736	740	MAPK	MAPK	NN	B-NP
O	740	741	)	)	)	O
O	742	745	and	and	CC	O
O	746	762	phosphoinositide	phosphoinositide	NN	B-NP
O	763	764	3	3	CD	I-NP
O	764	765	-	-	HYPH	I-NP
O	765	771	kinase	kinase	NN	I-NP
O	772	773	(	(	(	O
O	773	777	PI3K	PI3K	NN	B-NP
O	777	778	)	)	)	O
O	779	788	signaling	signaling	NN	B-NP
O	788	789	.	.	.	O

O	790	803	Pharmacologic	Pharmacologic	JJ	B-NP
O	804	810	agents	agent	NNS	I-NP
O	811	815	have	have	VBP	B-VP
O	816	820	been	be	VBN	I-VP
O	821	831	identified	identify	VBN	I-VP
O	832	836	that	that	WDT	B-NP
O	837	843	target	target	VBP	B-VP
O	844	849	these	these	DT	B-NP
O	850	858	pathways	pathway	NNS	I-NP
O	858	859	,	,	,	O
O	860	863	yet	yet	RB	B-ADVP
O	864	867	for	for	IN	B-PP
O	868	872	some	some	DT	B-NP
O	873	879	agents	agent	NNS	I-NP
O	880	881	(	(	(	O
O	881	888	notably	notably	RB	B-NP
O	889	900	thalidomide	thalidomide	NN	I-NP
O	900	901	)	)	)	O
O	901	902	,	,	,	O
O	903	905	an	an	DT	B-NP
O	906	919	understanding	understanding	NN	I-NP
O	920	922	of	of	IN	B-PP
O	923	926	the	the	DT	B-NP
O	927	935	specific	specific	JJ	I-NP
O	936	946	mechanisms	mechanism	NNS	I-NP
O	947	949	of	of	IN	B-PP
B-Cancer	950	959	antitumor	antitumor	JJ	B-NP
O	960	966	action	action	NN	I-NP
O	967	970	has	have	VBZ	B-VP
O	971	977	proved	prove	VBN	I-VP
O	978	985	elusive	elusive	JJ	B-ADJP
O	985	986	.	.	.	O

O	987	990	The	The	DT	B-NP
O	991	1000	following	follow	VBG	I-NP
O	1001	1007	review	review	NN	I-NP
O	1008	1017	describes	describe	VBZ	B-VP
O	1018	1021	key	key	JJ	B-NP
O	1022	1031	molecular	molecular	JJ	I-NP
O	1032	1042	mechanisms	mechanism	NNS	I-NP
O	1043	1046	and	and	CC	O
O	1047	1052	novel	novel	JJ	B-NP
O	1053	1062	therapies	therapy	NNS	I-NP
O	1063	1067	that	that	WDT	B-NP
O	1068	1071	are	be	VBP	B-VP
O	1072	1074	on	on	IN	B-PP
O	1075	1078	the	the	DT	B-NP
O	1079	1086	horizon	horizon	NN	I-NP
O	1087	1090	for	for	IN	B-PP
O	1091	1105	antiangiogenic	antiangiogenic	JJ	B-NP
B-Cancer	1106	1111	tumor	tumor	NN	I-NP
O	1112	1119	therapy	therapy	NN	I-NP
O	1119	1120	.	.	.	O

